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Objectives: The prospective multinational Survey of Osteoarthritis Real World 
Therapies (SORT) was designed to investigate treatment patterns, adequacy of 
pain relief and quality of life in knee osteoarthritis (OA). This analysis describes 
the demographic and clinical characteristics most associated with inadequate 
pain relief (IPR) in knee OA in Portugal. MethOds: Male or female subjects aged 
≥ 50 years with primary knee OA and who were receiving oral or topical analgesics 
were enrolled between January and December 2011 at seven primary care cent-
ers. Pain was assessed using the Brief Pain Inventory (BPI). IPR was defined as a 
score > 4/10 on the BPI item “What is your pain on average?” reflecting moderate 
to severe disease. Multivariable logistic regression model was employed to iden-
tify the subject characteristics most associated with IPR. Results: Overall, 197 
consecutive patients were analyzed. The mean age was 67.0 ± 8.6 years and 78.2% 
were female. The mean duration of knee OA was 6.2 ± 6.3 years. The most com-
mon comorbidities were hypertension (64.0%), hyperlipidemia (58.4%), disability 
(41.6%) and depression (37.6%). Nonsteroidal antiinflammatory drugs were the 
most frequently used analgesics. IPR was reported by 51.3% of patients (95%CI 
44.1%, 58.4%). Disability, depression and diabetes were more frequent among 
patients with IPR than in patients with Non-IPR (p< 0.05). No statistically signifi-
cant differences were observed in the type and mean number of different classes 
of medication used by IPR and Non-IPR patients. Female gender (adjusted odds 
ratio - OR 2.15 [95%CI 1.1, 4.5]), diabetes (adjusted OR 3.1 [95%CI 1.3, 7.7]) and 
depression (adjusted OR 2.24 [95%CI 1.2, 4.3]) were associated with higher risk of 
IPR. cOnclusiOns: Our findings indicate that improvements are needed in the 
management of pain in knee OA in order to achieve better outcomes and highlight 
the requisite for further interventions targeting frequent comorbid conditions in 
knee OA in Portugal.
PMS105
Patient RePoRted outcoMe in HealtH SeRviceS ReSeaRcH: a 
PRoSPective Study of oRtHoPedic SuRgeRy in Routine caRe in 
SwitzeRland
Eichler K1, Hess S1, Twerenbold C1, Grobet C2, Flury M2, Wieser S1, Audigé L2
1Winterthur Institute of Health Economics, Zurich University of Applied Sciences, Winterthur, 
Switzerland, 2Schulthess Clinic, Zurich, Switzerland
Objectives: Rotator cuff tear of the shoulder is a common musculoskeletal disor-
der, may have a substantial impact on patients’ quality of life (QOL) and implies a 
significant cost burden. Arthroscopic rotator cuff repair (aRCR) is one established 
standard therapy, however, health services research has generated little infor-
mation about the impact of aRCR on QOL and on costs in real world settings. We 
aimed to assess the impact of aRCR in routine care in Switzerland. MethOds: In a 
prospective before-after study, consecutive patients with aRCR in a single tertiary 
orthopaedic centre were assessed for QOL using EQ-5D-5L to gain health states/
utilities (range: 0.00-1.00; multiple measurements from pre-operative enrolment 
until 2 years after surgery). Direct medical costs in Swiss Francs (CHF) were assessed 
from a third party payer perspective using health insurance claims data for 3 time 
intervals (1 year before surgery; year 1 and 2 after surgery). Results: 152 patients 
(mean age 57 years [range: 31-73]; male: 61%) were operated, of which 67 were evalu-
ated for QOL up to 12 months. QOL showed a stepwise improvement: 0.75 (mean 
utility at enrollment), 0.71 (pre-op), 0.61 (2 weeks), 0.85 (3 months), 0.91 (6 months), 
0.93 (12 months). Direct medical costs (mean, SD) of the first patients with cost 
data were CHF 7,540 (6,684) in the year before surgery (n= 47: mean inpatient: 882; 
outpatient: 6,658) and CHF 9,759 (3,675) in the first year after surgery (n= 40: mean 
inpatient: 4,964 [including operation]; outpatient: 4,795). cOnclusiOns: Patients 
with aRCR in routine care show a significant and clinically relevant improvement 
of QOL until 12 months after surgery. This is important information for decision 
makers in Switzerland. Completion of follow up of our patient cohort will allow a 
better understanding of the relationship between gain in QOL and involved direct 
medical costs.
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Objectives: The recently developed Forgotten Joint Score - 12 (FJS-12) is increas-
ingly being used in patients with hip or knee pathologies to assess joint aware-
ness following surgical or conservative treatment. Joint awareness is a construct 
considered to be especially relevant in patients with good to excellent outcome. In 
our study we aimed at investigating reliability, validity and sensitivity to change 
over time of the English version of the FJS-12 in patients with total knee arthro-
plasty (TKA) or total hip arthroplasty (THA). MethOds: Patients undergoing THA 
or TKA at the Royal Infirmary of Edinburgh were consecutively included in the 
study and assessed with the FJS-12 at pre-surgery, 6 months and 12 months. To 
determine convergent validity we administered the Oxford Hip Score (OHS) and 
the Oxford Knee Score (OKS). We calculated Cronbach’s Alpha as a measure of 
internal consistency of the FJS-12. Sensitivity to change is given as effect size 
(Cohen’s d). Results: At present we have recruited 219 TKA patients and 193 
THA patients (recruitment ongoing). Mean age of the TKA patients was 68.3 (SD 
9.3) and 54.1% were female. Mean age in the THA group was 67.6 years (SD 10.5) 
and 116 (60.1%) were female. Cronbach’s alpha was very high in both groups (0.95 
in TKA patients and 0.96 in THA patients). Correlations with the OHS (r= 0.76) and 
the OKS (r= 0.72) indicated good convergent validity of the FJS-12. Effect sizes 
for change between 6 months and 12 months in FJS-12 scores were 0.40 in TKA 
patients and d= 0.17 in THA patients. cOnclusiOns: The English version of 
the FJS-12 showed high internal consistency in THA and TKA patients and good 
convergent validity with the OHS and OKS. Our findings suggest that the FJS-
12 is a reliable and valid instrument for the assessment of outcome after THA 
and TKA.
patient organizations wasn’t perceived significant. Areas that have improved com-
pared to the period of patients starting their treatment: communication with health-
care personnel (80%), more effective therapies available (65%). cOnclusiOns: This 
study showed significant impact of the rheumatic diseases on work capabilities and 
socio-economic status. The results of the research were presented and discussed with 
the patient community and rheumatologists and on their respective conferences.
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Objectives: Chronic autoimmune diseases such as rheumatoid arthritis (RA) 
require continuous disease modifying medication to influence disease progres-
sion. Real-life efficacy of treatments rests on adherence. Since patients’ beliefs 
impact on adherence, adherence could be supported by treatments better respect-
ing these beliefs. Thus, using an RA sample, the present study establishes in how 
far patients’ beliefs are reflected by their preferences for treatment characteristics 
of disease-modifying anti-rheumatic drugs (DMARDs). MethOds: Preferences 
were assessed in a choice experiment (Best-Worst Scaling). 1588 RA patients were 
asked to choose most and least preferred DMARDs among treatment options with 
varying levels of the following key attributes: mode of administration, frequency 
of administration, time till onset of drug effect, necessity of combination therapy, 
and side effects. Patients were classified into groups of “accepting”, “ambivalent”, 
“sceptical”, and “indifferent” patients (Clifford et al., 2008) according to a modified 
“beliefs about medicines”-questionnaire. Utilities of attribute levels were assessed 
by paired model regression analysis (Flynn et al., 2007) and compared between 
groups. Regression analysis was conducted to control for confounding patient-
related variables. Results: Majority of patients were female (74%), 50 to 64 years 
of age (45%), with < 10 years of disease duration (54%), and were receiving DMARDs 
(95%). Mode of administration appeared the most important attribute, with “oral 
application“ being most desired. Second most relevant attribute was “necessity 
of combination therapy with MTX”, followed by frequency of administration, side 
effects and time to onset of effect. Preferences concerning “mode of administration” 
and “tolerance of side effects” were significantly different between subjects clas-
sified by their beliefs about medicines”, according to regression analysis adjusting 
for confounding patient-related variables. cOnclusiOns: Results indicate beliefs 
about medicines to be meaningfully associated with patient preferences regard-
ing DMARD characteristics. This offers important leads to improving adherence by 
designing more consumer-friendly pharmaceutical products for chronic diseases.
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Objectives: To synthesize the available information on patients’ preferences for 
rheumatoid arthritis (RA) treatment and their participation in the treatment deci-
sion-making process. MethOds: Electronic databases [PubMed, ISI-WOK, Cochrane 
Library, MEDES, IBECS, CSIC] and grey literature, were searched. Studies written in 
English or Spanish, published in Europe and North America between January 2005 
and February 2015 were selected. Editorials, letters, opinion papers and studies 
performed on specific populations were excluded. Results: The search resulted in 
1,156 citations; 15 studies accomplished the selection criteria. Nine studies explored 
patients’ preferences for RA treatments characteristics (administration methods= 7; 
frequency= 2). Auto-injected devices that facilitated self-administration at home 
and improved comfort, and less frequent doses were preferred. Convenience (home 
administration and non-interference with everyday life) was the main reason for 
choosing subcutaneous routes, while safety, rapidity of action, reassurance and con-
fidence were the reasons for choosing intravenous routes. Two publications exam-
ined the influence of patients’ characteristics on treatment status-quo. Patients 
who were moderately affected by RA were more open to consider new treatment 
alternatives. One study explored patients’ priorities regarding treatment outcomes. 
Less pain, joint damage or fatigue, daily life activities and more mobility were the 
prioritized outcomes. Three studies elicited preferences regarding patients’ par-
ticipation in treatment decision-making, showing that they were negatively asso-
ciated with age but positively associated with RA knowledge. Although patients 
preferred shared treatment decision-making, they reported that most of the phy-
sician-patients communication was centered on symptoms and impact of RA. Most 
patients valued treatment recommendations given by their physicians considering 
their expert knowledge and clinical experience. Unawareness of having a choice 
was the main barrier for patients’ participation in decision-making. cOnclusiOns: 
Patients’ preferences are influenced by patients’ characteristics, clinical status and 
impact of RA in their daily life. Including patients’ preference and involving patients 
in treatment decision-making may contribute to better clinical outcomes.
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compared to HAQ-DI (0.004 improvement in utility per unit decrease in PASI). Using 
these algorithms, the incremental cost-effectiveness ratios (ICER) were calculated 
for each biologic versus standard of care. For each biologic ICERs coefficient of vari-
ation (standard deviation/mean) was approx. 17%. cOnclusiOns: HAQ-DI is the 
key influencing variable in deriving utility values for PsA patients in the current 
algorithms. In biologic cost-effectiveness models, ICER is sensitive to the algorithms 
used. The analysis suggests that there may be a need of an improved algorithm to 
inform cost-effectiveness models for predicting utility more accurately. This may 
help the healthcare decision makers to make more informed decisions.
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Objectives: The aim of this study was to assess the disease activity and quality of 
life of patients with ankylosing spondylitis (AS) in Polish population. MethOds: 
On-line questionnaire survey was performed to obtain data on disease activity 
and the quality of life. We used Bath Ankylosing Spondylitis Disease Activity Index 
(BASDAI) and EQ-5D questionnaires with visual analogue scale (VAS). BASDAI score 
was obtained using on-line calculator. EQ-5D states were converted into utilities for 
European population. The Spearman’s correlation was used to present the associa-
tion between the disease activity and the quality of life. Results: A total number of 
66 questionnaires was obtained. Patients reported mostly the problems with general 
discomfort and morning stiffness represented by 8 points on BASDAI scale, followed 
by tiredness and neck pain represented by 7 points and other pain represented by 5 
points. Almost 30% of patients reported that morning stiffness lasts longer than two 
hours. The mean BASDAI score was 5.87 (SD: 1.81). Of all patients, 68% reported some 
(highest reported state) problems with mobility, 47% with looking after himself. A lot 
(highest reported state) of problems with usual activities reported 4% of patients, a 
lot of pain and discomfort was reported by 13% of patients and with feeling worried 
by 6%. In all domains “some problems” was the most frequent answer resulting that 
the most common EQ-5D state was “22222”. The mean utility was 0.52 (SD: 0.195) 
varied from 0 to 1. Patient reported visual analogue scale was 47 (SD: 26) varied 
from 0 to 100. BASDAI score was significantly correlated with utility (-0.635) and VAS 
(-0.620). cOnclusiOns: Ankylosing spondylitis significantly reduces the quality of 
life. The higher the BASDAI score representing the higher disease activity and the 
lower the quality of life, reported as both EQ-5D utility and VAS.
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Objectives: Non-radiographic axial spondyloarthritis (nr-axSpA) is an inflammatory 
arthritic disease characterized by sacroiliac joint inflammation. Studies indicate that 
nr-axSpA is a long-term chronic condition and can impose a considerable burden on 
the patients’ physical function, impairment, and health-related quality of life. This 
analysis aimed to investigate whether elements of the burden associated with nr-
axSpA are avoidable. MethOds: Data were from the 2014 nr-axSpA Disease Specific 
Programme, a cross-sectional, multi-national survey of patients and rheumatolo-
gists conducted in France, Germany, Italy, Spain and the UK. Rheumatologists com-
pleted forms containing patient demographics, clinical results and symptomology. 
Patients completed patient self-completions (PSCs) containing the Work Productivity 
and Activity Impairment questionnaire and EuroQoL-5D (EQ-5D-3L) with the visual 
analogue scale (EQ-VAS). Biologic treatment naïve patients considered eligible for bio-
logics by the physician were compared to patients receiving biologics for ≥ 6 months. 
Observations were weighted to ensure findings were more representative of the 
patient population. The weight was applied to all percentages, means and standard 
deviations (SDs). Appropriate weighted univariate regressions were performed to 
test for significance. Results: The analysis comprised of 310 patients (mean age 
42.5±11.8 [SD], 74.8% male), with 123 biologic-naïve and 187 biologic-treated patients. 
Only 76 PSCs were completed in total. Compared to biologic-treated patients, biologic-
naïve patients had greater overall work impairment (37.1% vs. 18.8%), presentee-
ism (27.6% vs. 15.8%) and activity impairment (31.4% vs. 22.5%). Additionally, more 
biologic-naïve patients were currently experiencing acute episodes (12.7% vs. 2.5%) 
and inflammatory back pain (69.5% vs. 38.5%) (all p< 0.05). There were no observed 
differences between cohorts regarding mean EQ-5D utility score (0.81 vs. 0.82) or 
EQ-VAS (65.5 vs. 64.8). cOnclusiOns: A potential unmet has been highlighted in 
nr-axSpA patient management, which could be due to restrictions upon physicians 
prescribing choices. Reducing the duration between diagnosis and biologic treatment 
prescription could potentially lessen the societal and clinical burden of nr-axSpA.
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Objectives: To describe residual skin and joint disease and health-related qual-
ity of life (HRQoL) in psoriatic arthritis (PsA) patients treated with biologics, and 
explore the impact of residual disease on HRQoL, work productivity, and switching 
therapies. MethOds: This was a retrospective analysis of 2013/14 US-EU5 Adelphi 
Real World cross-sectional survey data from dermatologists, rheumatologists, and 
PsA patients receiving biologics for ≥ 6-months. Outcomes included: EuroQol-5 
Dimension (EQ-5D), Health Assessment Questionnaire Disability Index (HAQ-DI) 
(rheumatologists), PROMIS-HAQ) (dermatologists), Dermatology Life Quality Index 
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Objectives: To determine which patient-reported outcome (PRO) tools were 
used in studies on musculoskeletal diseases published in 2014. MethOds: An 
evidence surveillance process was established based on a systematic search 
of PubMed, incorporating all studies published from 2010 and updated weekly, 
with a final search on 18 May 2015. Abstracts identified by the search that 
reported quality of life outcomes in musculoskeletal disorders were identified. 
Articles were included if they reported results or a study protocol from a primary 
research study or were a systematic review. PRO tools were identified from the 
abstract alone, where possible. Results: The search identified 1,980 articles 
published in 2014. Of these, 197 (10%) were in musculoskeletal disorders. The 
most commonly researched diseases were osteoarthritis (19 articles), rheu-
matoid arthritis and back pain (14 each), fibromyalgia and fractures (10 each), 
and ankylosing spondylitis (9). Overall, 160 different PRO or clinician-reported 
instruments were cited in the 197 abstracts, with 93 articles citing more than 
one tool. Pain instruments were most commonly used (82 articles included 
either VAS or unspecified pain measurement). Utility measurement was made 
in 36 studies, with SF-36 used twice as often as either SF-12 or EQ-5D. PROs most 
commonly cited included WOMAC (13 articles), DASH (9), KOOS (9), HAQ (8), 
WHOQOL-BREF (6), FIQ and WOSI (5 each). The PRO used was not specified in 52 
article abstracts: 22 of the 143 primary research articles, 7 of 18 study protocols 
and 30 of 34 systematic reviews. cOnclusiOns: A wide range of musculoskel-
etal disorders were researched in 2014, with little overlap in PRO tools used 
even within diseases. Standardisation of tool use would aid comparison of out-
comes across studies. Evidence surveillance including study protocols, results 
and systematic reviews may help identify trends in PRO use within specific 
diseases.
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Objectives: Fibromyalgia is a chronic pain syndrome characterized by increased 
sensitivity to pain, fatigue, muscle stiffness, difficulty sleeping, problems with 
mental processes (known as “fibro-fog”), such as problems with memory and con-
centration, headaches, and irritable bowel syndrome. The objectives of this study 
were 1) to identify patient-reported outcome (PRO) claims in products specifically 
approved for the treatment of fibromyalgia by the Food and Drug Administration 
(FDA) and the European Medicines Agency (EMA) since 1995, and 2) to identify 
the endpoint positioning of the PROs when measured. MethOds: The websites 
of the FDA and the EMA were explored to identify all products approved specifi-
cally for fibromyalgia. PROLabels was used to identify products with a PRO claim 
in label. All corresponding clinical reviews (FDA), and assessments reports (EMA) 
were reviewed to check for endpoint positioning. Results: Since 1995, only three 
products have been approved with the specific indication of fibromyalgia (three by 
the FDA, i.e., duloxetine, milnacipran and pregabalin). None have been approved by 
the EMA. All of the products approved by the FDA include PRO claims in their label: 
reduction in pain, improvements in function, and in patient global impression of 
change (PGIC). When the medical review was available (duloxetine, milnacipran), 
the analysis of endpoint positioning showed that reduction in pain (either meas-
ured by the overall score of the Brief Pain Inventory or a Visual Analog Scale) was 
the primary efficacy endpoint. In one case (duloxetine), and for one study, the PGIC 
was also considered as a primary endpoint. Function was a secondary endpoint 
measured either by the Fibromyalgia Impact Questionnaire (duloxetine, pregaba-
lin) or the SF-36 Physical Component Summary (milnacipran). cOnclusiOns: 
PROs are essential to the evaluation of fibromyalgia products and are included in 
the labels of all products approved by the FDA. Reduction in pain is the key primary 
endpoint.
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Objectives: To evaluate the relationship between the disease activity measures 
(HAQ, PASI) and patient’s QoL based on different utility mappings and its influ-
ence on cost-effectiveness (CE) MethOds: The identified algorithms of a litera-
ture research project that includes database screening of publications in English 
language from 1996-2015 have been extracted and the differences have been 
explored in a CE model for PsA. The model follows a decision tree for the first 12 
weeks and Markov structure for rest of the time horizon with three month cycle 
length. Results: The research retrieved 13 different algorithms to derive utilities in 
PsA patients based on clinical study data. In these studies, utilities were measured 
either with the SF-36 (n= 5) or the EQ-5D (n= 9) instruments. Different algorithms 
used different independent variables such as HAQ-DI, PASI or Disease Activity Score 
28 (DAS28) to predict utility values. The arthritis component of the disease was 
measured either through HAQ-DI (n= 11) or DAS28 (n= 2), whereas PASI was used 
for the skin component (n= 4). Most of the algorithms were using a linear approach 
(n= 11). Among these linear algorithms one unit decrease of HAQ-DI improves 
patient’s utility by 0.1 to 0.3 units. Effect of PASI on utility was much smaller as 
